Low-intensity laser therapy to boost immune response in children with pneumonia
Impact of Low Intensity Laser Therapy on Immune System Response Among Children With Pneumonia
This trial will test whether adding low-intensity laser therapy to breathing exercises and usual medical care helps immune markers and breathing in children with Down syndrome and pneumonia.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 3 Years to 5 Years |
| Sex | All |
| Sponsor | Badr University Academic / other |
| Locations | 1 site (Cairo) |
| Trial ID | NCT07552116 on ClinicalTrials.gov |
What this trial studies
Forty children with Down syndrome and bronchopneumonia were assigned to two equal groups; both groups received standard medical treatment and inspiratory muscle training with postural drainage, while one group also received low-intensity laser therapy. Treatments were delivered three times per week for one month. Blood markers (WBC, IgG, IgA, IgM) and respiratory measures (respiratory rate and oxygen saturation) were measured before and after the one-month program. The study compares changes in immune and respiratory outcomes between the laser-plus-exercise group and the exercise-only group.
Who should consider this trial
Good fit: Children with Down syndrome experiencing a first episode of bronchopneumonia, roughly preschool age (mean ~3.7 years in the study), who can attend center-based therapy and do inspiratory muscle training are the intended candidates.
Not a fit: Children with other chronic chest diseases, recurrent or complicated pneumonia, older children or adults, or those unable to tolerate the procedures are unlikely to receive benefit from this specific protocol.
Why it matters
Potential benefit: If successful, adding low-intensity laser therapy could improve immune markers and oxygenation and speed recovery in children with Down syndrome who have pneumonia.
How similar studies have performed: Previous small studies of low-level laser therapy for immune modulation show limited and mixed results, so using it for pneumonia in children with Down syndrome is relatively novel and not yet widely validated.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Dawn Syndrome children with pneumonia * Mean age of 3.73±1.82 year * Children were in the first attack of bronchopneumonia. Exclusion Criteria: * Other chest disease
Where this trial is running
Cairo
- Mona Mohamed Abdelkhalek — Cairo, Egypt (Recruiting)
Study contacts
- Principal investigator: Mona Mohamed Abdelkhalek, assistance prof — Badr University
- Study coordinator: Mona Mohamed Abdelkhalek, assistance professor
- Email: mona.abdelkhalek@buc.edu.eg
- Phone: 00201024056108
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.